Drug Profile
Ronomilast
Alternative Names: AWD 12353; ELB 353Latest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator ASTA Medica
- Developer Acorda Therapeutics
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Chronic obstructive pulmonary disease
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Hypersensitivity
Most Recent Events
- 09 Apr 2024 Discontinued - Phase-I for Chronic obstructive pulmonary disease (In volunteers) in Germany (PO) as company files for bankruptcy
- 09 Apr 2024 Discontinued - Preclinical for Hypersensitivity in Germany (PO) as company files for bankruptcy
- 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in Germany (PO)